In a 2-year study, empagliflozin as add-on to metformin demonstrated significantly greater decreases in hemoglobin A1c (a measure of average blood glucose over the past 2 to 3 months), body weight and blood pressure compared with glimepiride as add-on to metformin in adults with type 2 diabetes.
In a 2-year study, empagliflozin as add-on to metformin demonstrated significantly greater decreases in hemoglobin A1c (a measure of average blood glucose over the past 2 to 3 months), body weight and blood pressure compared with glimepiride as add-on to metformin in adults with type 2 diabetes.
Data from the study of 1,545 randomized and treated adults with type 2 diabetes that compared the efficacy and safety profiles of empagliflozin 25 mg with glimepiride, each in combination with metformin, were presented at the American Diabetes Association (ADA) Scientific Sessions in San Francisco.
Other findings included:
Significantly fewer hypoglycemic events were reported for empagliflozin compared with glimepiride (2.5% vs. 24.2%, respectively). Overall adverse event rates in the two arms were 86.4% and 86.3% for empagliflozin and glimepiride, respectively. Urinary tract infections were reported in 13.7% of patients in the empagliflozin arm and 13.1% of patients in the glimepiride arm, and genital infections were reported in 11.8% and 2.2% for empagliflozin and glimepiride, respectively.
“This study was conducted to compare the efficacy and safety profiles of empagliflozin 25 mg with glimepiride, each in combination with metformin among patients with type 2 diabetes,” said Christophe Arbet-Engels, MD, PhD, vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals. “This new data adds to the clinical profile for empagliflozin and bolsters its large clinical registration program.”
Boehringer Ingelheim and Eli Lilly and Company sponsored the study.
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More